These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 23459219)

  • 41. Alteration of intracellular Ca2+ transients in COS-7 cells transfected with the cDNA encoding skeletal-muscle ryanodine receptor carrying a mutation associated with malignant hyperthermia.
    Treves S; Larini F; Menegazzi P; Steinberg TH; Koval M; Vilsen B; Andersen JP; Zorzato F
    Biochem J; 1994 Aug; 301 ( Pt 3)(Pt 3):661-5. PubMed ID: 8053891
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Core myopathies and malignant hyperthermia susceptibility: a review.
    Brislin RP; Theroux MC
    Paediatr Anaesth; 2013 Sep; 23(9):834-41. PubMed ID: 23617272
    [TBL] [Abstract][Full Text] [Related]  

  • 43. [Malignant hyperthermia. The ugly].
    Rüffert H; Wehner M; Deutrich C; Olthoff D
    Anaesthesist; 2007 Sep; 56(9):923-9. PubMed ID: 17565473
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Next-generation DNA sequencing of a Swedish malignant hyperthermia cohort.
    Broman M; Kleinschnitz I; Bach JE; Rost S; Islander G; Müller CR
    Clin Genet; 2015 Oct; 88(4):381-5. PubMed ID: 25256590
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Heat production during anesthetic-induced malignant hyperthermia.
    Nelson TE
    Biosci Rep; 2001 Apr; 21(2):169-79. PubMed ID: 11725865
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Risk of malignant hyperthermia in patients carrying a variant in the skeletal muscle ryanodine receptor 1 gene.
    Janssens L; De Puydt J; Milazzo M; Symoens S; De Bleecker JL; Herdewyn S
    Neuromuscul Disord; 2022 Dec; 32(11-12):864-869. PubMed ID: 36283893
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Effects of Remimazolam and Propofol on Ca
    Watanabe T; Miyoshi H; Noda Y; Narasaki S; Morio A; Toyota Y; Kimura H; Mukaida K; Yasuda T; Tsutsumi YM
    Biomed Res Int; 2021; 2021():8845129. PubMed ID: 33490280
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Congenital ptosis, scoliosis, and malignant hyperthermia susceptibility in siblings with recessive RYR1 mutations.
    AlBakri A; Karaoui M; Alkuraya FS; Khan AO
    J AAPOS; 2015 Dec; 19(6):577-9. PubMed ID: 26691049
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Duchenne muscular dystrophy and malignant hyperthermia: a genetic study of the ryanodine receptor in 47 patients.
    Rohde D; Schmitt HJ; Winterpacht A; Münster T
    Eur J Anaesthesiol; 2014 Jun; 31(6):341-2. PubMed ID: 24557023
    [No Abstract]   [Full Text] [Related]  

  • 50. Identical de novo mutation in the type 1 ryanodine receptor gene associated with fatal, stress-induced malignant hyperthermia in two unrelated families.
    Groom L; Muldoon SM; Tang ZZ; Brandom BW; Bayarsaikhan M; Bina S; Lee HS; Qiu X; Sambuughin N; Dirksen RT
    Anesthesiology; 2011 Nov; 115(5):938-45. PubMed ID: 21918424
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Myopathic changes in malignant hyperthermia-susceptible patients.
    Rosenberg H
    Can J Anaesth; 2013 Oct; 60(10):955-9. PubMed ID: 23897489
    [No Abstract]   [Full Text] [Related]  

  • 52. Spontaneous occurrence of the disposition to malignant hyperthermia.
    Rueffert H; Olthoff D; Deutrich C
    Anesthesiology; 2004 Mar; 100(3):731-3. PubMed ID: 15108991
    [No Abstract]   [Full Text] [Related]  

  • 53. RYR1 variant c.38T>G, p.Leu13Arg causes hypersensitivity of the ryanodine receptor-1 and is pathogenic for malignant hyperthermia.
    van den Bersselaar LR; Greven T; Bulger T; Voermans NC; van Petegem F; Schiemann AH; Parker R; Burling SM; Jungbluth H; Stowell KM; Kamsteeg EJ; Snoeck MMJ
    Br J Anaesth; 2021 Aug; 127(2):e63-e65. PubMed ID: 34127251
    [No Abstract]   [Full Text] [Related]  

  • 54. Diseases associated with altered ryanodine receptor activity.
    Durham WJ; Wehrens XH; Sood S; Hamilton SL
    Subcell Biochem; 2007; 45():273-321. PubMed ID: 18193641
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Malignant hyperthermia.
    Bouchama A; Hussain S
    Lancet; 1998 Nov; 352(9142):1785. PubMed ID: 9848381
    [No Abstract]   [Full Text] [Related]  

  • 56. Sex-specific alterations in whole body energetics and voluntary activity in heterozygous R163C malignant hyperthermia-susceptible mice.
    Rutkowsky JM; Knotts TA; Allen PD; Pessah IN; Ramsey JJ
    FASEB J; 2020 Jun; 34(6):8721-8733. PubMed ID: 32367593
    [TBL] [Abstract][Full Text] [Related]  

  • 57. An Exciting Couple.
    Etlinger JD
    J Pediatr Ophthalmol Strabismus; 2018 May; 55(3):149-150. PubMed ID: 29796677
    [No Abstract]   [Full Text] [Related]  

  • 58. Functional analysis of
    Stephens J; Schiemann AH; Roesl C; Miller D; Massey S; Pollock N; Bulger T; Stowell K
    Temperature (Austin); 2016; 3(2):328-339. PubMed ID: 27857962
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Identification of variants of the ryanodine receptor type 1 in patients with exertional heat stroke and positive response to the malignant hyperthermia in vitro contracture test.
    Roux-Buisson N; Monnier N; Sagui E; Abriat A; Brosset C; Bendahan D; Kozak-Ribbens G; Gazzola S; Quesada JL; Foutrier-Morello C; Rendu J; Figarella-Branger D; Cozonne P; Aubert M; Bourdon L; Lunardi J; Fauré J
    Br J Anaesth; 2016 Apr; 116(4):566-8. PubMed ID: 26994242
    [No Abstract]   [Full Text] [Related]  

  • 60. Malignant hyperthermia and associated disorders.
    Allen GC
    Curr Opin Rheumatol; 1993 Nov; 5(6):719-24. PubMed ID: 8117533
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.